Christan D. Santos

Christan D. Santos

Auto-generated profile, based on publicly available information

Christan D. Santos

Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL 32224, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
KZKaneez Zahra
Kaneez Zahra
RDRicardo A. Domingo
Ricardo A. Domingo
MTMarion T. Turnbull
Marion T. Turnbull
CSChristan D. Santos
Christan D. Santos
SPSarah H. Peacock
Sarah H. Peacock
WFWilliam D. Freeman
William D. Freeman
Objective: To report the preliminary safety, tolerability, and cerebral spinal fluid (CSF) sampling utility of serial injections of concentrated intraventricular nicardipine (IVN) in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). Methods: We report the clinical, radiographic, and laboratory safety and tolerability data of a retrospective case series from a single academic medical center. All patients with aSAH developed vasospasm despite enteral nimodipine and received serial injections of concentrated IVN (2.5 mg/mL). CSF injection safety, tolerability, and utility are defined and reported. Results: A total of 59 doses of concentrated IVN were administered to three patients with poor-grade SAH. In Case 1, a 33-year-old man with modified Fisher scale (mFS) grade 4 and Hunt-Hess scale (HH) score 4 received 26 doses; in Case 2, a 36-year-old woman with mFS grade 4 and HH score 5 received 13 doses; and in Case 3, a 70-year-old woman with mFS grade 3 and HH score 4 received 20 doses. No major safety or tolerability events occurred. Two patients were discharged to a rehabilitation facility, and one died after discharge from the hospital. Conclusions: A concentrated 4 mg IVN dose (2.5 mg/mL) in a 1.6 mL injection appears relatively safe and tolerable and potentially offers a second-line strategy for treating refractory vasospasm in poor-grade SAH without compromising intracranial pressure or cerebral perfusion pressure.

17 September 2019 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
CSChristan D. Santos
Christan D. Santos
NMNikki L. Matos
Nikki L. Matos
RARabea Asleh
Rabea Asleh
SDSara Dawit
Sara Dawit
ARAlejandro A. Rabinstein
Alejandro A. Rabinstein
WFWilliam D. Freeman
William D. Freeman

4 February 2021 in Journal of the American Association of Nurse Practitioners
Verified
Journal Article
Closed access
CSChristan D. Aprn Santos
Christan D. Aprn Santos
AGAmi A. Aprn Grek
Ami A. Aprn Grek
MOMichelle M. Pa-C Ojard
Michelle M. Pa-C Ojard
JPJoshua A. Pa-C Propst
Joshua A. Pa-C Propst
JHJacquelyn J. Pa-C Hastings
Jacquelyn J. Pa-C Hastings
JSJason L. Siegel
Jason L. Siegel
The coronavirus disease 2019 (COVID-19) pandemic has required swift implementation of innovative practices in health care across the globe. We describe a nurse practitioner (NP) and physician assistant (PA)–led initiative to implement telemonitoring (TM) of noncritical patients with COVID-19 by critical care NPs and PAs (C19TM) for early detection of decompensation and early transfer to the intensive care unit (ICU). Every hospitalized patient with suspected or confirmed COVID-19 received an initial telemedicine consult with a critical care NP or PA. Patients were subsequently monitored via electronic health record once every 12-hour shift for the following indicators: oxygen modality and flow, increase in oxygen requirements, sustained tachypnea, and hemodynamic instability. If signs of decompensation were noted, the NP/PA would remotely reassess the patient, provide recommendations to the hospital internal medicine team, and transfer the patient to the ICU. The primary goal was to avoid cardiopulmonary deterioration requiring aerosol-generating procedures outside of the ICU. Over 65 days, 113 patients (86 suspected and 27 confirmed) were enrolled in C19TM. As a result, there were 13 transfers to the ICU, none of which required an aerosol-generating procedure outside of the ICU.

16 June 2021 in Cureus
Verified
Journal Article
Open access
CSChristan D. Santos
Christan D. Santos
JPJoshua A Propst
Joshua A Propst
JCJuan M. Canabal
Juan M. Canabal
RGRohan Goswami
Rohan Goswami
Cardiac tamponade is a rare complication following orthotopic liver transplantation (OLT). The incidence and treatment specific to the immediate postoperative OLT patient have never been reported. Here, we describe a case of OLT complicated by coagulopathy and difficult intraoperative pulmonary artery catheter placement with subsequent postoperative hemopericardium resulting in tamponade. An emergent, ultrasound-guided, lateral-apical pericardiocentesis was successfully performed, suggesting a possible procedural technique for pericardiocentesis in the immediate postoperative period for liver transplant patients.

1 June 2021 in Critical Care Nurse
Verified
Journal Article
Open access
PDF file
CSChristan D. Santos
Christan D. Santos
MRMariah Q. Rose
Mariah Q. Rose
INTRODUCTION Antipsychotics are a treatment option for delirium in the intensive care unit. Atypical antipsychotics are preferred over first-generation antipsychotics because of their lower incidence of extra-pyramidal adverse effects. The most common such effect is akathisia or restlessness. This report describes a case of atypical antipsychotic-induced akathisia and addresses the clinical distinction between extrapyramidal movements and movements due to intensive care unit delirium. CLINICAL FINDINGS A 56-year-old man who had a prolonged hospital stay after orthotopic liver transplant complicated by multisystem organ failure, primary graft failure requiring a second transplant, and enterocutaneous fistula developed agitated delirium on hospital day 28. Initial treatment included intravenous haloperidol and scheduled sublingual olanzapine (5 mg daily). His delirium and insomnia persisted, requiring dexmedetomidine infusion. Olanzapine dosing was increased to 10 mg daily on hospital day 34 and 15 mg daily on hospital day 45. The following day, his mentation improved; however, he exhibited asynchronous, nonrhythmic, involuntary rolling motions of his hands and choreiform gait. DIAGNOSIS AND OUTCOMES Antipsychotics were immediately discontinued owing to acute akathisia. All symptoms resolved within 2 days, and the patient was transferred out of the intensive care unit on hospital day 52. CONCLUSION Although extrapyramidal adverse effects are less common with olanzapine than with typical antipsychotics, they sometimes occur and can mimic manifestations of delirium. Restlessness should alert the nurse to assess for possible extrapyramidal adverse effects. If they are suspected, antipsychotic medications should be reduced or discontinued to prevent progression to functional disability.

23 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NKNirmaljot Kaur
Nirmaljot Kaur
SYSiva Naga S. Yarrarapu
Siva Naga S. Yarrarapu
AGAbhishek R. Giri
Abhishek R. Giri
KPKathleen A. Rottman Pietrzak
Kathleen A. Rottman Pietrzak
CSChristan Santos
Christan Santos
DSDevang K. Sanghavi
Devang K. Sanghavi
Background Ketamine, a dissociative anesthetic, induces remission of depression by antagonizing glutaminergic NMDA receptors. Ketamine has been used previously in outpatient setting for treatment-resistant depression, but we showcase its utility in depression management at the Intensive Care Unit (ICU). Research Question Can ketamine be used for depression treatment in ICU patients? Study Design and Methods A retrospective chart review of ICU patients was done at a tertiary center from 2018 to 2021, to assess the ketamine usage. Among the patients reviewed, ketamine was used for depression in 12, and for analgesia & sedation in 2322 patients. Ketamine was administered in doses of 0.5mg/kg & 0.75mg/kg for depression. Each course consisted of 3 doses of ketamine administered over 3 days. 7 in 12 patients received a single course of ketamine. The rest received 3-4 courses 1 week apart. Results Ketamine was found to improve mood and affect in most of the patients with depression. 11 in 12 patients had a positive response with better sleep. It has a major advantage over conventional anti-depressants since it takes only a few hours to induce remission. Patients who refused to eat and follow treatment protocol, and who would otherwise succumb to death if not for the rapid remission of depression, were administered ketamine. Conclusion A major drawback of ketamine is that the duration of remission is short, with the response lasting only up to 7 days after a single dose. Hence, all the patients in our study were weaned off ketamine with a supporting antidepressant. Ketamine has been documented to cause cardio-neurotoxicity; however, only one patient had worsening lethargy in our study. To conclude, ketamine has a monumental benefit in treating depression in the ICU. Although our study was associated with positive outcomes, there is a need for prospective studies with long-term follow-up assessments.